| DC 欄位 |
值 |
語言 |
| DC.contributor | 統計研究所 | zh_TW |
| DC.creator | 謝佩倢 | zh_TW |
| DC.creator | Pei-jie Sie | en_US |
| dc.date.accessioned | 2013-7-18T07:39:07Z | |
| dc.date.available | 2013-7-18T07:39:07Z | |
| dc.date.issued | 2013 | |
| dc.identifier.uri | http://ir.lib.ncu.edu.tw:88/thesis/view_etd.asp?URN=100225013 | |
| dc.contributor.department | 統計研究所 | zh_TW |
| DC.description | 國立中央大學 | zh_TW |
| DC.description | National Central University | en_US |
| dc.description.abstract | 本文研究在兩期雙序列交叉設計之下，受試藥及專利藥的生物對等性檢定。如果之前具有類似學名藥的試驗，則研究者具備此一受試藥生體可用性的先驗知識。所以，本文考慮使用貝氏方法分析生體可用性衡量值的穩健隨機效應模式，進行兩種藥物的貝氏生物對等性檢定。本文除了利用實例說明所提穩健模式及貝氏生物對等性檢定的應用，並且使用模擬方法研究在各種可能的隨機效應模式之下，此一貝氏生物對等性檢定的表現。 | zh_TW |
| dc.description.abstract | The article considers the bioequivalence test between the test drug and patent drug under a 2×2 crossover design. If there have been some generic drugs under study, then prior information about the bioavailability of the test drugs
would be available. Therefore, this article considers a Bayesian test for the bioequivalence of the two drugs based on a robust random effects model for the estimated bioavailability parameters. A real data is illustrated based on the proposed Bayesian bioequivalent test. Finally, a simulation study is implemented to investigate the performance of the proposed test. | en_US |
| DC.subject | 生物對等性試驗 | zh_TW |
| DC.subject | 兩期雙序列交叉設計 | zh_TW |
| DC.subject | 生體可用性 | zh_TW |
| DC.subject | 貝氏方法 | zh_TW |
| DC.subject | 穩健隨機效應模式 | zh_TW |
| DC.subject | Bioequivalence test | en_US |
| DC.subject | 2×2 crossover design | en_US |
| DC.subject | Bioavailability | en_US |
| DC.subject | Bayesian method | en_US |
| DC.subject | Robust random effects model | en_US |
| DC.title | 生物對等性之貝氏檢定 | zh_TW |
| dc.language.iso | zh-TW | zh-TW |
| DC.type | 博碩士論文 | zh_TW |
| DC.type | thesis | en_US |
| DC.publisher | National Central University | en_US |